The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case–control study. Issue 3 (March 2017)

• Record Type: Journal Article
• Authors: Unger, Lukas W.; Herac, Merima; Staufer, Katharina; Salat, Andreas; Silberhumer, Gerd; Hofmann, Michael; Trauner, Michael; Rasoul-Rockenschaub, Susanne; Soliman, Thomas; Reiberger, Thomas; Berlakovich, Gabriela A.
• Is Part Of: European journal of gastroenterology & hepatology. Volume 29:Issue 3(2017:Mar.)
• Publication Date: 2017-03
• Subjects: liver fibrosis -- liver transplantation -- metabolic syndrome -- nonalcoholic fatty liver disease; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000000794
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Background: Nonalcoholic fatty liver disease (NAFLD) can be considered the hepatic manifestation of the metabolic syndrome with nonalcoholic steatohepatitis (NASH) as its progressive form. With increasing prevalence of the metabolic syndrome, NASH cirrhosis is becoming a leading cause for liver transplantation. Some cases of orthotopic liver transplantation (OLT) due to cryptogenic cirrhosis (CC) might show typical features of NASH cirrhosis. Therefore, our aim was to assess recurrence of liver fibrosis in patients transplanted for NASH versus CC after OLT. Patients and methods: Patients transplanted for CC or NASH between 1 January 2004 and 30 September 2015 were included. The histological NAFLD activity score and the NAFLD fibrosis score (NFS) were assessed. Results: In total, 15 and 12 patients underwent OLT because of NASH and CC, respectively. The case load for OLT because of NASH was constantly increasing ( n =2 in 2004–2007 vs. n =9 in 2012–2015) whereas decreasing for CC ( n =6 in 2004–2007 vs. n =2 in 2012–2015). Patient characteristics at OLT were similar, except for an older age and a higher BMI in NASH patients (59.1±2.2 vs. 51.8±2.9 years, P =0.05; 27.7±1.2 vs. 24.3±0.8 kg/m 2, P =0.035). Although post-OLT plasma lipid levels and incidence of de-novo hypertension, diabetes, and hyperlipidemia were similar between groups, the post-transplant NFS re-increased in the NASH group (but not in the CC: −0.1317 vs. −1.3645 at 12 months post-OLT, P =0.0400). Post-transplant survival was similar in NASH and CC patients. Conclusion: According to the NFS, some NASH patients show recurrence of fibrosis as early as 6–12 months after OLT.